trending Market Intelligence /marketintelligence/en/news-insights/trending/v-qjyg5l12sig9ztkdauja2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Mesoblast, Mallinckrodt sign equity deal; discuss development partnership

LK Bennett Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Mesoblast, Mallinckrodt sign equity deal; discuss development partnership

Mallinckrodt Pharmaceuticals is making an equity investment in Mesoblast Ltd.

The parties entered a purchase agreement under which Mallinckrodt will purchase 20.04 million Mesoblast shares at A$1.4761 apiece representing nearly 5% of the company.

The companies are also negotiating a commercial and development partnership to advance two of Mesoblast's drug candidates in phase 3 clinical trial.

MPC-06-ID is being developed for the treatment of chronic back pain due to disc degeneration, while MSC-100-IV is being evaluated as a front-line therapy for children with a certain type of transplant complication.

Mallinckrodt has nine months to conclude negotiations for the rights to both candidates in all territories outside of China and Japan.

As of Dec. 22, US$1 was equivalent to A$1.38.